Release Details

Business update to include masked Phase 3 patient demographics and baseline characteristics

Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California

MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 15, 2025 at 5:15 PM PT.

Dr. Guerard will provide an update on the business, including masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials. Opthea’s executive team will attend the conference and be available for one-on-one meetings January 13-16, 2025.

The live webcast and presentation will be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/, where the replay will be available for 30 days.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com   

Source: Opthea Limited

Source: Opthea Limited